Cannabinoids for MS Spasticity and Pain: What the Clinical Trials Show

What the researchers found

This review synthesized evidence from randomized trials on cannabinoid use for two of the most troubling MS symptoms: spasticity and pain.

Several randomized trials provided Class 1 and 2 evidence (the highest levels) supporting cannabinoid products for these indications. However, the optimal ratio of THC to CBD and the ideal dosing were not yet established.

The review raised an important cautionary note: the safety and long-term cognitive effects of cannabinoid products in people with MS have not been evaluated. Since short-term memory and processing speed are already significantly impaired in many MS patients, the potential for cannabinoids to worsen cognitive function is a particular concern in this population.

Why it matters

MS spasticity and pain significantly affect quality of life and are often inadequately managed by existing treatments. Having Class 1-2 evidence supporting cannabinoids is notable, but the cognitive concern is especially important because MS patients cannot afford additional cognitive burden.

The numbers in context

Class 1 and 2 evidence from multiple randomized trials. Optimal THC:CBD ratio and doses not yet determined. Short-term memory and processing speed already impaired in many MS patients.

How the study worked

Clinical review of randomized controlled trials examining cannabinoid products for spasticity and pain in MS, published in Current Treatment Options in Neurology.

What this study cannot tell us

The review noted that optimal dosing and formulation remain undefined. Long-term safety data in MS patients are lacking. The cognitive concern, while theoretically important, has not been systematically studied in cannabis-using MS patients.

How to read the evidence

This review draws on Class 1 and 2 evidence (randomized controlled trials), providing strong evidence for efficacy in MS spasticity and pain.

When this study was published

Published in 2016. Additional clinical experience and some longer-term data on cannabinoids in MS have accumulated since then.

The bigger picture

Cannabinoids represent one of the better-studied treatment options for MS symptoms, with higher-quality evidence than exists for many other conditions. The tension between symptom relief and cognitive risk reflects a broader challenge in MS treatment: many effective medications carry cognitive or fatigue side effects.

Questions still open

• Do cannabinoid products worsen cognitive function in MS patients? Can formulations be optimized to provide symptom relief while minimizing cognitive effects?

Common questions

Read the original research

Use of Cannabinoids for Spasticity and Pain Management in MS.

Current treatment options in neurology, 18(1), 1

Citation

Chohan, Hardeep; Greenfield, Ariele L; Yadav, Vijayshree; Graves, Jennifer. (2016). Use of Cannabinoids for Spasticity and Pain Management in MS.. Current treatment options in neurology, 18(1), 1. https://doi.org/10.1007/s11940-015-0385-y

Explore the wider topic

• CBD Oil Quality Guide: How to Avoid Snake Oil
• Anxiety After Quitting Weed: When to Consider Medication
• Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
• Cannabis for Chronic Pain: What the Research Actually Supports
• Cannabis and Epilepsy: The Epidiolex Story and What It Means
• Does CBD Actually Work for Anxiety? What the Evidence Shows
• Does CBD Help with Weed Withdrawal? What Studies Show
• CBD vs THC: The Differences That Actually Matter
• The Proven Medical Benefits of Cannabis: What Research Supports
• Quitting Weed Before Surgery
• Weed and Medications: What Changes When You Quit
• Quitting Weed During Pregnancy: What You Need to Know
• Quitting Weed While Pregnant: What You Need to Know
• Cannabis and Older Adults: Risks Seniors Should Know
• Cannabis and Breastfeeding: THC in Breast Milk